News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
678,751 Results
Type
Article (38792)
Company Profile (247)
Press Release (639712)
Section
Business (203548)
Career Advice (1977)
Deals (35351)
Drug Delivery (78)
Drug Development (80633)
Employer Resources (167)
FDA (16013)
Job Trends (14780)
News (343744)
Policy (32417)
Tag
Academia (2528)
Africa (710)
Alliances (48988)
Alzheimer's disease (1138)
Approvals (15937)
Arizona (173)
Artificial intelligence (68)
Asia (36783)
Australia (5979)
Bankruptcy (350)
Best Places to Work (11254)
Biosimilars (63)
Biotechnology (173)
C2C Services and Suppliers (78803)
California (1785)
Canada (908)
Cancer (398)
Career advice (1647)
Cell therapy (113)
China (136)
Clinical research (63131)
Collaboration (129)
Colorado (71)
Compensation (73)
Connecticut (69)
COVID-19 (2485)
Cystic fibrosis (72)
Data (228)
Diabetes (79)
Diagnostics (5964)
Drug pricing (61)
Earnings (83646)
Employer resources (142)
Europe (78650)
Events (107725)
Executive appointments (137)
FDA (16211)
Florida (254)
Funding (135)
Gene therapy (88)
GLP-1 (506)
Government (4286)
Healthcare (18605)
Hotbed/Location (481000)
Illinois (247)
Indiana (144)
Infectious disease (2512)
Inflammatory bowel disease (88)
Interviews (306)
IPO (16188)
Job creations (3620)
Job search strategy (1412)
Kansas (94)
Layoffs (393)
Legal (7828)
Lung cancer (90)
Manufacturing (82)
Maryland (375)
Massachusetts (1453)
Medical device (13030)
Medtech (13035)
Mergers & acquisitions (19009)
Metabolic disorders (240)
Michigan (123)
Minnesota (212)
Neuroscience (1271)
New Jersey (541)
New York (561)
NextGen Class of 2024 (6480)
Non-profit (4455)
North Carolina (578)
Northern California (794)
Obesity (143)
Ohio (103)
Opinion (172)
Patents (66)
Pennsylvania (566)
People (55818)
Pharmaceutical (60)
Phase I (19556)
Phase II (27798)
Phase III (20782)
Pipeline (103)
Postmarket research (2553)
Preclinical (8307)
Press Release (64)
Rare diseases (126)
Real estate (5881)
Recruiting (63)
Regulatory (21179)
Research institute (2304)
Resumes & cover letters (346)
South America (1084)
Southern California (725)
Startups (3559)
Texas (222)
United States (8193)
Vaccines (464)
Washington State (244)
Weight loss (124)
Date
Last 7 days (657)
Last 30 days (2049)
Last 365 days (37114)
2024 (25671)
2023 (40078)
2022 (51178)
2021 (55715)
2020 (54094)
2019 (46545)
2018 (35025)
2017 (32114)
2016 (31484)
2015 (37562)
2014 (31322)
2013 (26358)
2012 (28577)
2011 (29273)
2010 (27334)
678,751 Results for "ucb inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
UCB Offloads Neurology, Allergy Portfolio in China for $680M
Belgium-based biopharma UCB is selling its Chinese neurology and allergy business to Singapore asset management firm CBC Group and Abu Dhabi investment company Mubadala.
August 26, 2024
·
1 min read
·
Annalee Armstrong
Drug Development
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa
UCB today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX.
May 23, 2024
·
14 min read
BioMidwest
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
UCB announced the first presentation of two-year data from the Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, and the open-label extension, BE MOVING, evaluating BIMZELX, an interleukin -17A and IL-17F inhibitor, in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis, also known as radiographic axial spondyloarthritis.
June 12, 2024
·
21 min read
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
April 12, 2024
·
70 min read
Press Releases
UCB and University Health Network (UHN) Collaborate to Enhance Axial Spondyloarthritis (axSpA) Care in Canada
August 2, 2024
·
4 min read
UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
UCB, a global biopharmaceutical company, today unveiled its extensive program of 29 studies, including 4 late breakers, accepted for presentation at the AES Annual Meeting 2023, taking place from 1-5 December in Orlando, Florida.
December 1, 2023
·
28 min read
FDA
UCB Wins FDA Approval for Plaque Psoriasis Therapy After Regulatory Setbacks
Following a delay and an initial rejection, UCB’s IL-17A/IL-17F blocker bimekizumab was approved for moderate-to-severe plaque psoriasis, which will now be marketed with the brand name Bimzelx.
October 19, 2023
·
2 min read
·
Tristan Manalac
BioMidwest
UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
UCB announced that BIMZELX® is commercially available for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
November 14, 2023
·
14 min read
FDA
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that ZILBRYSQ® (zilucoplan) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
October 17, 2023
·
27 min read
Business
ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio.
May 24, 2023
·
4 min read
1 of 67,876
Next